Director, Business Intelligence, PNH

We are seeking a talented and energetic Director, Business Intelligence (BI) - EMPAVELI who will play a key role in the commercialization of EMPAVELI in PNH. The Director will be accountable for partnering closely with U.S. commercial, and cross-functional teams to generate market-specific insights from sales and performance analytics and primary market research, to create integrated, actionable insights for cross-functional stakeholder groups across the organization. The ideal candidate must have significant experience working in a commercial insights and analytics position within a biotech or biopharma company, focusing on rare diseases (hematology a plus). The Director will report to the Senior Director, Business Intelligence & Commercial Operations - EMPAVELI, and is expected to drive market knowledge and insights that foster cross-functional action, shaping strategy and tactical execution for EMPAVELI in PNH in the US., * Own brand performance/sales analytics/reporting, including national and subnational analyses

• Partner with the brand lead and relevant cross-functional stakeholders to design and execute strategic primary market research to track brand performance/address key business questions
• BI lead for strategic brand initiatives (e.g., brand planning, tactical planning), providing market outlooks, situation assessments, and SWOT analyses
• Develop expert knowledge across the therapeutic area, including but not limited to competitive landscape (marketed and pipeline), market dynamics, customer behavior, and sentiment
• Partner with Forecasting and maintain a strong understanding of the forecast and provide/validate assumptions that inform the brand forecast
• Proactively scope key business questions, generate hypotheses, independently design studies/analyses, and generate insights for the business with a strong focus on foresight
• Own the annual insights budget for EMPAVELI in PNH

• B.S. degree required (business, biology, or medicine-related degree preferred); advanced Degree (MBA, PhD, PharmD) preferred
• 10+ years in an insights and analytics function within a biotech or biopharma organization
• Must-Haves:
• Hands-on strong analytics and modeling skills in Excel; familiarity with BI tools such as Power BI
• Experience in rare disease
• Expertise with claims, EMR, and registry datasets to generate strategic/actionable insights
• Expertise in qualitative and quantitative market research methodologies
• Excellent project and vendor management skills; ability to run multiple cross-disciplinary projects simultaneously (e.g., sales analytics, claims analyses, market research) with competing timelines
• Excellent cross-functional collaboration and leadership skills; ability to influence across several levels of the organization, including executive leadership, without authority
• Strategic and analytical mindset; strong problem-solving/framing abilities
• Excellent communication skills; able to integrate insights from multiple sources, create simplicity from complexity, and articulate compelling solution-driven narratives that foster action

• Managerial courage: ability to challenge and persuade different/cross-functional audiences within the organization, including business and executive leadership

• Seasoned in commercial assessments, asset evaluation, and prioritization, Bachelor’s Degree

Benefits and Perks: Apellis offers a comprehensive benefits package, inclusive flexible time off, summer and winter shutdowns, paid family leave and more!

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases.